Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Antibody-drug conjugates in urothelial carcinoma

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, explores the use of antibody-drug conjugates (ADCs) in urothelial carcinoma, including enfortumab vedotin and sacituzumab govitecan which are approved by the US FDA in this patient population. Future directions include moving established ADCs into earlier treatment lines, as well as novel anti-HER2 ADCs including disitamab vedotin. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.